IXHL · Incannex Healthcare Inc.
$3.21
+0.04 (+1.26%)
At close · Jul 20
Market Cap
$38.41M
Shares
11.96M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$86K
+616.7%
FY2025
Net Income
-$46.89M
-154%
FY2025
Operating Margin
-27661.63%
+222680pp
FY2025
Diluted EPS
-$40.50
-17.4%
FY2025
Operating Cash Flow
-$12.51M
+21%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | $86K | $12K | — | |
| — | — | $172K | — | |
| $7.42M | $10.75M | $12.88M | $6.31M | |
| $17.94M | $13.13M | $17.17M | $8.01M | |
| — | $246K | $103K | $88K | |
| $25.37M | $23.88M | $30.05M | $49.67M | |
| -$25.37M | -$23.79M | -$30.04M | -$49.67M | |
| — | -27661.63% | -250341.67% | — | |
| — | -$23.54M | -$29.94M | -$49.58M | |
| $349K | $303K | — | — | |
| — | $62K | $206K | $241K | |
| -$23.05M | -$23.1M | $11.61M | $857K | |
| -$48.41M | -$46.89M | -$18.43M | -$48.81M | |
| — | — | $30K | — | |
| -$48.41M | -$46.89M | -$18.46M | -$48.81M | |
| — | -54517.44% | -153825% | — | |
| -$48.58M | -$46.68M | -$18.54M | -$51.1M | |
| USD/shares | — | -$40.50 | -$34.50 | -$99.60 |
| USD/shares | — | -$40.50 | -$34.50 | -$99.60 |
| shares | — | 1.15M | 538.81K | 512.82K |
| shares | — | 1.15M | 538.81K | 512.82K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - Specialty & Generic median 2.22×
EV/EBIT
—
Drug Manufacturers - Specialty & Generic median 34.74×
P/E (TTM)
—
Drug Manufacturers - Specialty & Generic median 19.97×